<DOC>
	<DOCNO>NCT00907062</DOCNO>
	<brief_summary>Vitiligo common hypopigmentation disorder significant psychological impact occur adulthood . One study investigate use Ginkgo biloba treatment vitiligo adult report effectiveness , significant flaw . We endeavor conduct open label pilot clinical trial replicate previous trial 12 adolescent 12 18 year old . The purpose pilot test feasibility recruitment patient retention , variability outcome measure , identify major safety concern . The pilot use 60 mg standardize G. biloba two time per day ( BID ) 12 week . The primary outcome validate Vitiligo European Task Force ( VETF ) evaluation form , secondary outcome include Vitiligo Area Scoring Index ( VASI ) , assess repigmentation via photograph , monitor report adverse reaction .</brief_summary>
	<brief_title>Ginkgo Biloba Treatment Vitiligo Vulgaris Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Vitiligo</mesh_term>
	<criteria>• male females 12 18 year old self select candidate identify suffer vitiligo vulgaris duration minimum VASI score 4 , maximum score ( correspond 3cm2 completely ( 100 % ) depigmented lesion , 6cm2 50 % depigmented lesion ) stable progress vitiligo mentally competent subject able adhere give protocol treatment administer intervention normal physical examination prestudy intake , case abnormality health care practitioner considers clinically insignificant write informed consent potential candidate must family doctor see last 12 month negative pregnancy test menstruate woman sexually active , willingness practice adequate birth control duration trial diagnosis vitiligo confirm supervise medical doctor • use medication contraindicate Ginkgo biloba : daily use acetylsalicylic acid , ibuprofen , NSAIDs , fish oil , vitamin E prescription use blood thinner , anticoagulant , antiplatelet drug , pentoxifylline , clot factor replacement , antihypertensive medication , Thiazide diuretic , Acetylcholinesterase inhibitor , anticonvulsant , hypoglycemic agent , MAOI , SSRI , Nifedipine , Papaverine , Yohimgine , Sildenafil history diabetes , seizure , haemophilia allergy sensitivity Ginkgo biloba constituent capsule treatment vitiligo within last 2 month current use Ginkgo biloba within last 2 month mentally physically incapacitated assent inform consent obtain . history condition study physician regard clinically significant study major illness consider clinically significant study physician within 2 month study start date current participation another intervention trial . pregnancy intent become pregnant next 4 month current alcoholism substance abuse . current history tumor , history skin cancer current serious disorder determine clinically significant study . breast feeding woman prior skin graft surgery , schedule surgery kind . abnormality INR , PTT , CBC test baseline</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>vitiligo</keyword>
	<keyword>leucoderma</keyword>
</DOC>